These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 22669600)

  • 21. Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index.
    Kawashiri SY; Kawakami A; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Yamasaki S; Nakamura H; Ueki Y; Migita K; Mizokami A; Origuchi T; Aoyagi K; Eguchi K
    Mod Rheumatol; 2011 Aug; 21(4):365-9. PubMed ID: 21229375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical effect of tocilizumab on patients with severe active rheumatoid arthritis].
    Xu S; Xie X; Tang M; Chen J; Tian J; Du J; Mao N; Liu Y; Li S; Song M; Gao J; Ling G; Li F
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Oct; 42(10):1174-1177. PubMed ID: 29093249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tight control of rheumatoid arthritis in a resource-constrained setting: a randomized controlled study comparing the clinical disease activity index and simplified disease activity index.
    Hodkinson B; Musenge E; Tikly M
    Rheumatology (Oxford); 2015 Jun; 54(6):1033-8. PubMed ID: 25431484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fatigue in rheumatoid arthritis: quantitative findings on the efficacy of tocilizumab and on factors associated with fatigue. The French multicentre prospective PEPS Study.
    Gossec L; Steinberg G; Rouanet S; Combe B
    Clin Exp Rheumatol; 2015; 33(5):664-70. PubMed ID: 26344671
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tocilizumab treatment increases left ventricular ejection fraction and decreases left ventricular mass index in patients with rheumatoid arthritis without cardiac symptoms: assessed using 3.0 tesla cardiac magnetic resonance imaging.
    Kobayashi H; Kobayashi Y; Giles JT; Yoneyama K; Nakajima Y; Takei M
    J Rheumatol; 2014 Oct; 41(10):1916-21. PubMed ID: 25128513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Serum Tocilizumab Trough Concentrations with Clinical Disease Activity Index Scores in Adult Patients with Rheumatoid Arthritis.
    Arad U; Elkayam O
    J Rheumatol; 2019 Dec; 46(12):1577-1581. PubMed ID: 31154416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sleep disturbances and interleukin 6 receptor inhibition in rheumatoid arthritis.
    Fragiadaki K; Tektonidou MG; Konsta M; Chrousos GP; Sfikakis PP
    J Rheumatol; 2012 Jan; 39(1):60-2. PubMed ID: 22133618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reexamination of the assessment criteria for rheumatoid arthritis disease activity based on comparison of the Disease Activity Score 28 with other simpler assessment methods.
    Fujiwara M; Kita Y
    Mod Rheumatol; 2013 Mar; 23(2):260-8. PubMed ID: 22546955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index.
    Aletaha D; Martinez-Avila J; Kvien TK; Smolen JS
    Ann Rheum Dis; 2012 Jul; 71(7):1190-6. PubMed ID: 22454398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tocilizumab in patients with active rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs or tumor necrosis factor inhibitors: subanalysis of Spanish results of an open-label study close to clinical practice.
    Álvaro-Gracia JM; Fernández-Nebro A; García-López A; Guzmán M; Blanco FJ; Navarro FJ; Bustabad S; Armendáriz Y; Román-Ivorra JA;
    Reumatol Clin; 2014; 10(2):94-100. PubMed ID: 24099961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
    Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
    J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients.
    Aletaha D; Funovits J; Keystone EC; Smolen JS
    Arthritis Rheum; 2007 Oct; 56(10):3226-35. PubMed ID: 17907167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group.
    Tugwell P; Wells G; Strand V; Maetzel A; Bombardier C; Crawford B; Dorrier C; Thompson A
    Arthritis Rheum; 2000 Mar; 43(3):506-14. PubMed ID: 10728742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level.
    Funahashi K; Koyano S; Miura T; Hagiwara T; Okuda K; Matsubara T
    Mod Rheumatol; 2009; 19(5):507-12. PubMed ID: 19609487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice.
    Bykerk VP; Östör AJ; Alvaro-Gracia J; Pavelka K; Román Ivorra JA; Graninger W; Bensen W; Nurmohamed MT; Krause A; Bernasconi C; Aassi M; Sibilia J
    Clin Rheumatol; 2015 Mar; 34(3):563-71. PubMed ID: 25604316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis.
    van der Kooij SM; de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Ewals JA; Han KH; Hazes JM; Kerstens PJ; Peeters AJ; van Zeben D; Breedveld FC; Huizinga TW; Dijkmans BA; Allaart CF
    Arthritis Rheum; 2009 Jan; 61(1):4-12. PubMed ID: 19116965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in atherosclerosis markers during tocilizumab treatment in rheumatoid arthritis: preliminary results.
    Benucci M; Manfredi M; Saviola G; Sarzi-Puttini P; Atzeni F
    Clin Exp Rheumatol; 2013; 31(2):322-3. PubMed ID: 23380047
    [No Abstract]   [Full Text] [Related]  

  • 38. Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study.
    Kojima T; Yabe Y; Kaneko A; Takahashi N; Funahashi K; Kato D; Hanabayashi M; Asai S; Hirabara S; Asai N; Hirano Y; Hayashi M; Miyake H; Kojima M; Ishiguro N
    Rheumatology (Oxford); 2015 Jan; 54(1):113-20. PubMed ID: 25102861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of different remission definitions on identification of predictors of both point and sustained remission in rheumatoid arthritis treated with anti-TNF therapy.
    Barnabe C; Homik J; Barr SG; Martin L; Maksymowych WP
    J Rheumatol; 2014 Aug; 41(8):1607-13. PubMed ID: 25028371
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI.
    Suzuki T; Horikoshi M; Sugihara M; Hirota T; Ogishima H; Umeda N; Kondo Y; Tsuboi H; Hayashi T; Chino Y; Matsumoto I; Sumida T
    Mod Rheumatol; 2013 Jul; 23(4):782-7. PubMed ID: 22975733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.